Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Corcept Therapeutics       

CORCEPT THERAPEUTICS
Mes dernières consult.
Most popular
  Report  
 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 160 M
EBIT 2017 53,9 M
Net income 2017 55,5 M
Debt 2017 -
Yield 2017 -
Sales 2018 265 M
EBIT 2018 125 M
Net income 2018 130 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 36,89
P/E ratio 2018 17,09
Capi. / Sales2017 11,3x
Capi. / Sales2018 6,79x
Capitalization 1 800 M
More Financials
Company
Corcept Therapeutics, Inc. engages in the development of drugs for the treatment of severe psychiatric, neurological, and metabolic disorders.It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol.Its products include korlym and korlym... 
Sector
Pharmaceuticals
Calendar
02/22Earnings Release
More about the company
Surperformance© ratings of Corcept Therapeutics
Trading Rating : Investor Rating :
More Ratings
Latest news on CORCEPT THERAPEUTICS
07:06pCORCEPT THERAPEUTICS INCORPORATED : Corcept Therapeutics Incorporated. to Host E..
AC
02/15Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2017 Financial ..
GL
02/05CORCEPT THERAPEUTICS INCORPORATED (N : CORT) Files An 8-K Other Events
AQ
02/05CORCEPT THERAPEUTICS INC : Other Events (form 8-K)
AQ
02/01CORCEPT THERAPEUTICS INCORPORATED : Announces Preliminary Fourth Quarter and Ful..
PU
02/01CORCEPT THERAPEUTICS INC : Regulation FD Disclosure, Financial Statements and Ex..
AQ
02/01Corcept Therapeutics Announces Fourth Quarter and Full-Year 2017 Preliminary ..
GL
01/17CORCEPT THERAPEUTICS INCORPORATED (N : CORT) Files An 8-K Regulation FD Disclosu..
AQ
01/17CORCEPT THERAPEUTICS INC : Regulation FD Disclosure (form 8-K)
AQ
2017CORCEPT THERAPEUTICS INCORPORATED : INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF ..
AQ
More news
Sector news : Pharmaceuticals - NEC
02:56pNOVARTIS : Greek Parliament Investigates Politicians in Novartis Bribery Probe
DJ
07:21aSeed firms scramble to stop a 'cancer' in Canada's cash crop
RE
02/21ASTRAZENECA : U.S. health officials reverse stance on AstraZeneca's flu vaccine
RE
02/21MERCK : to Invest Additional EUR40 Million in Asia
DJ
02/21Merck to buy virus-based cancer drug firm Viralytics for $394 million
RE
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/26BIOTECH : The Gates Begin To Open 
2017HEALTHCARE GAINERS / LOSERS AS OF 11 : 30 am 
2017Wait For Alphabet To Go Down Before Buying - Cramer's Lightning Round (12/21/.. 
2017HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am 
2017Interactive Brokers, Corcept Therapeutics, Alarm.com moving into S&P indices 
Chart CORCEPT THERAPEUTICS
Duration : Period :
Corcept Therapeutics Technical Analysis Chart | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 21,5 $
Spread / Average Target 36%
EPS Revisions
Managers
NameTitle
Joseph K. Belanoff President, Chief Executive Officer, Director & MD
James N. Wilson Chairman
Gary Charles Robb Secretary & Chief Financial Officer
Robert S. Fishman Chief Medical Officer
Hazel Hunt Senior Vice President-Research
Sector and Competitors
1st jan.Capitalization (M$)
CORCEPT THERAPEUTICS38.87%1 800
JOHNSON & JOHNSON-6.33%349 006
NOVARTIS-2.67%224 221
PFIZER-0.58%213 155
ROCHE HOLDING LTD.-9.33%206 183
MERCK AND COMPANY-2.29%148 618